Article thumbnail

The impact of biologics on health-related quality of life in patients with inflammatory bowel disease

By Lauran Vogelaar, Adriaan van’t Spijker and C Janneke van der Woude
Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3108643
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). [Biological therapy as treatment of inflammatory bowel diseases]. Ugeskr Laeger.
  2. (1989). 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med.
  3. (1996). A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care.
  4. A randomized, placebocontrolled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease.
  5. A randomized, placebocontrolled, double-blind trial of mesalamine in the maintenance of remission of Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group.
  6. A study of the association between Crohn’s disease and psychiatric illness.
  7. Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece.
  8. (1998). Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study Group.
  9. (2003). Burden of illness of Crohn’s disease in Spain. Dig Liver Dis.
  10. Certolizumab pegol for the treatment of Crohn’s disease.
  11. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care.
  12. (2004). Coping strategies and quality of life of adolescents with inflammatory bowel disease. Qual Life Res.
  13. Cost of illness of Crohn’s disease.
  14. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.
  15. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis.
  16. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease.
  17. (2005). Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis.
  18. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.
  19. (2000). Determining minimally important changes in generic and disease-specific healthrelated quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum.
  20. (1999). Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr.
  21. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial.
  22. (2002). Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res.
  23. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases.
  24. Group CDPCsDS. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn’s disease.
  25. Group IS. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis.
  26. Health-related quality of life during natalizumab maintenance therapy for Crohn’s disease.
  27. High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency.
  28. (2006). Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis.
  29. (1999). Impact of inflammatory bowel disease on health-related quality of life. Dig Dis.
  30. Impact of surgery for Crohn’s disease on health-related quality of life.
  31. (2005). Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis.
  32. Incidence of inflammatory bowel disease
  33. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south?
  34. (1988). Incidence of inflammatory bowel disease in northern
  35. (1998). Incidence of inflammatory bowel disease in the area of Liege: a 3 years prospective study (1993–1996). Acta Gastroenterol Belg.
  36. (1992). Inflammatory bowel disease: costs-of-illness.
  37. (2002). Infliximab improves quality of life in patients with Crohn’s disease. Inflamm Bowel Dis.
  38. Influence of inflammatory bowel disease on different dimensions of quality of life.
  39. Interpreting SF-36 summary health measures: a response. Qual Life Res. 2001;10:405–413; discussion 415–420.
  40. (2002). Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis.
  41. (1994). Low-dose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial Investigators.
  42. (2003). Maintenance therapy for inflammatory bowel disease.
  43. Maintenance therapy with certolizumab pegol for Crohn’s disease.
  44. (1994). Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther.
  45. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group.
  46. (1996). Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc.
  47. (1995). Methotrexate for the treatment of Crohn’s disease.
  48. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs.
  49. North of England IBSRG. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.
  50. (1994). Oral budesonide for active Crohn’s disease.
  51. Predictors of disease-related concerns and other aspects of health-related quality of life in outpatients with inflammatory bowel disease.
  52. (1997). Quality of life issues in patients with inflammatory bowel disease.
  53. (1994). Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology.
  54. (1995). Quality-of-life results of doubleblind, placebo-controlled trial of mesalamine in patients with Crohn’s disease. Dig Dis Sci.
  55. reduce the need for healthcare in patients with Crohn’s disease. Inflamm Bowel Dis.
  56. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.
  57. (2007). Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis.
  58. (2007). Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflamm Bowel Dis.
  59. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
  60. (1998). The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment.
  61. (2002). The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflamm Bowel Dis.
  62. The rating form of IBD patient concerns: a new measure of health status.
  63. (1995). The relationship of psychiatric illness with gastrointestinal disease. Annu Rev Med.
  64. (1993). The SF-36 health survey manual and interpretation guide.
  65. Unemployment and disability in patients with moderately to severely active Crohn’s disease.